---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-21-011226"
form_type: "8-K"
ticker: "MGTX"
cik: "0001735438"
company_name: "MeiraGTx Holdings plc"
filed_at: "2021-08-11T23:59:59+00:00"
generated_at: "2026-06-29T15:21:53.679301+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# MeiraGTx Q2 net loss $20.1M ($0.46/sh); cash runway into Q2 2023

## Summary
- Net loss attributable to shareholders $20.1M ($0.46/sh) vs $25.4M ($0.69/sh) in Q2 2020.
- License revenue $5.1M (up from $2.5M); R&D spend $15.2M, G&A $10.4M.
- Cash and equivalents $172.6M (down from $194.8M); believes funded into Q2 2023.
- Expects to initiate Phase 3 Lumeos trial for XLRP, Phase 3 for AAV-RPE65, and file IND for AAV-GAD in Parkinsons in H2 2021.
- Manufacturing facility to support at least six clinical programs in next 12 months.

## SEC filing metadata
- accession: 0001558370-21-011226
- form_type: 8-K
- ticker: MGTX
- cik: 0001735438
- company_name: MeiraGTx Holdings plc
- filed_at: 2021-08-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1735438/000155837021011226/0001558370-21-011226-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1735438/000155837021011226/mgtx-20210811x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-21-011226
- JSON: https://secwatch.observer/filing/0001558370-21-011226.json
- Plain text: https://secwatch.observer/filing/0001558370-21-011226.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.